all

Adding ezetimibe to statin therapy further lowered cholesterol levels and resulted in fewer cardiovascular events in patients following heart attack
 

More than a decade ago, researchers from Brigham and Women’s Hospital (BWH) demonstrated that a high dose statin, which lowered cholesterol further than a regular dose statin, provided better clinical outcomes. But questions remained about whether further reducing cholesterol would be even more effective in reducing cardiovascular-related events.

On Sunday, Nov. 16, at the American Heart Association (AHA) Scientific Sessions, W. Virgil Brown, MD—Editor-in-Chief of the Journal of Clinical Lipidology and Founding President of the National Lipid Association (NLA)—facilitated and participated in a debate about cholesterol targets. The session (which also featured commentary from Dr. Jennifer Robinson of Iowa City) provided an opportunity to engage in thoughtful dialogue with global cardiovascular thought leaders about cholesterol targets.

By Peter H. Jones, MD, FACP, FNLA

The National Lipid Association (NLA) is excited about the upcoming 2014 American Heart Association (AHA) Scientific Sessions (Nov. 15-19, Chicago). This is the premier meeting exploring all of the latest news and science related to heart and vascular disease, and we’ll be on-site engaging in conversations with thought leaders and researchers from around the world. You should know that this meeting attracts more than 17,000 attendees from 100 countries.